Pfizer (PFE) stock declined slightly despite a strong earnings report on Tuesday as investors focused on the company’s quarterly results. PFE stock performance year-to-date stands at -4.94%, while its performance over the last seven days is just below -6.22%. For the past month, the stock’s price index fell by -4.94%, and over the previous three-month period, the stock’s price index rose by 4.06%. The stock has performed -3.73% in the last six months and -1.57% in the past 52 weeks.
According to Pfizer, COVID-19 vaccines developed in partnership with german biotechnology company BioNTech; BNTX) will generate about $15 billion in sales by 2021, a quarter of Pfizer’s projected revenue this year. Pfizer’s management expects total revenues in 2020 to range between $ 59.4 billion and $ 61.4 billion, better than analysts’ forecasts of $ 56.72 billion. The company has also increased its full-year profit forecast from a range of $3.00 – $3.10 to a range of $3.10 to $3.20, which compares with a forecast of $3.19.
Top 5 EV Tech Stocks to Buy for 2023
According a new report published by BloombergNEF on investment in the energy transition, annual spending on passenger EVs hit $388 billion in 2022, up 53% from the year before. Like we said, the boom is accelerating – and the time to buy EV-related tech stocks is now.
Click Here to Download the FREE Report.
According to Pfizer’s most recent financial statements, the company had shipped 65 million doses of vaccines worldwide and 29 million doses in the United States. According to Pfizer, it is on track to deliver 120 million doses by the end of March for $19.50 a dose. By the end of May, Pfizer will deliver 200 million doses to the United States. Sanofi, a French drug manufacturer, recently partnered with the company to manufacture dose.
According to the Centers for Disease Control and Prevention, 17 million Pfizer (PFE) vaccines have already been given.
The most important financial performance metric for a business is its profit. Each investor in a business gets extremely excited when earnings reports are released, and share prices rise when earnings exceed market expectations and fall when earnings do not live up to expectations.
Pfizer (PFE) reported an EPS of $0.42 during the last quarter ended on 12/30/2020 compared to an estimated EPS of $0.48, which means this quarter’s earnings fell short of estimates, with a surprise factor of -12.50%. Looking at current quarter EPS estimates that will end on Mar 2021, the average EPS estimate of $0.8 is in front of us. These six analysts offered EPS estimates that ranged between $0.98 and $0.66. Similarly, an average revenue estimate of $12.8B appears from 5 analysts, where the high revenue estimate is $15.07B, and the low revenue estimate is $10.56B for the current quarter.